<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30059" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Thioridazine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Feinberg</surname>
            <given-names>Shana M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fariba</surname>
            <given-names>Kamron A.</given-names>
          </name>
          <aff>University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shana Feinberg declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamron Fariba declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30059.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Similar to other first-generation or typical antipsychotics, thioridazine is a medication used to treat schizophrenia. Other indications for use include other psychotic disorders, depressive disorders, pediatric behavioral disorders, and geriatric psychoneurotic manifestations. This activity outlines the indications, mechanism of action, administration methods, significant adverse effects, contraindications, toxicity, and monitoring, of thioridazine, so providers can direct patient therapy where they are indicated as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of thioridazine.</p></list-item><list-item><p>Review the approved and off-label indications for thioridazine.</p></list-item><list-item><p>Summarize the contraindications and adverse event profile of thioridazine.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who can benefit from therapy with thioridazine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30059&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30059">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30059.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Similar to other first-generation, or typical antipsychotics, thioridazine is a medication with the United States Food and Drug Administration approval to treat schizophrenia and schizophrenia spectrum disorders.<xref ref-type="bibr" rid="article-30059.r1">[1]</xref><xref ref-type="bibr" rid="article-30059.r2">[2]</xref>&#x000a0;Its use today is mainly limited to refractory schizophrenia. Other off-label uses include depression with psychotic features, pediatric behavioral disorders, and geriatric psychoneurotic manifestations.<xref ref-type="bibr" rid="article-30059.r3">[3]</xref><xref ref-type="bibr" rid="article-30059.r4">[4]</xref>&#x000a0;It is not a first-line therapeutic choice for schizophrenia due to its adverse event profile. The brand-name version of this medication was withdrawn by its manufacturer from the market worldwide in 2005 because of adverse effects, notably cardiac arrhythmias, although generic versions remain available.<xref ref-type="bibr" rid="article-30059.r5">[5]</xref>&#x000a0;Thioridazine combined with other antibiotics is effective against drug-resistant tuberculosis, although there is no trial data to support its use for this indication.<xref ref-type="bibr" rid="article-30059.r6">[6]</xref></p>
      </sec>
      <sec id="article-30059.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Typical antipsychotics, including thioridazine, work to treat psychosis by blocking dopamine (DA) receptors. These medications effectively treat the positive symptoms of schizophrenia, such as hallucinations, delusions, and disorganization. Positive symptoms are believed to manifest as a result of increased levels of dopamine in the mesolimbic pathway. More specifically, thioridazine blocks DA-2 receptors in the mesolimbic pathway, diminishing positive symptoms. Thioridazine is classified as a low-potency first-generation antipsychotic, and as such, is relatively sedating. Thioridazine is a substrate of the hepatic enzyme cytochrome P450 (CYP450) 2D6 and is also an inhibitor of the same enzyme.&#x000a0;The drug also exhibits activity at muscarinic receptors (most notably the M1 receptor), which is most likely the source of its anticholinergic effects (eg, dry mouth, constipation), the alpha 1A adrenergic receptor (which may explain its association with orthostatic hypotension), the H1 histamine receptor (probably accounting for much of its sedating effect), and the <italic toggle="yes">hERG</italic> gene, which is likely responsible for its cardiotoxicity.<xref ref-type="bibr" rid="article-30059.r7">[7]</xref></p>
      </sec>
      <sec id="article-30059.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Thioridazine is an oral medication taken in tablet form. The tablets come in either 10&#x000a0;mg, 15 mg, 25&#x000a0;mg, 50&#x000a0;mg, 100 mg, 150 mg, or 200 mg.&#x000a0;For refractory schizophrenia, dosing recommendations are to initiate thioridazine at 50&#x000a0;mg to 100 mg three times per day and gradually increase the dose as indicated to a maximum of 800 mg per day. Prescribers must be aware of&#x000a0;the risk of inducing dose-dependent QTc prolongation,&#x000a0;hence the suggestion to start with a lower dose and&#x000a0;increase slowly. Thioridazine also comes in liquid form at 30 mg/mL and 100 mg/mL.&#x000a0;</p>
      </sec>
      <sec id="article-30059.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Extrapyramidal Side Effects&#x000a0;</bold>
</p>
        <p>Similar to other typical antipsychotics, thioridazine is associated with&#x000a0;a risk of developing extrapyramidal side effects (EPS). Because it is a low-potency antipsychotic, however, the development of EPS occurs less frequently than with high-potency antipsychotics. Extrapyramidal side effects include symptoms of dystonia, parkinsonism, and tardive dyskinesia. Dystonic reactions are muscle spasms that may occur early on and involve the eyes, tongue, or neck. Dystonic reactions&#x000a0;precipitate in response to the decreased ratio of dopamine to acetylcholine and thus are treatable by normalizing the ratio with anticholinergic medications, such as&#x000a0;benztropine or diphenhydramine. It is essential to monitor patients for dystonia to avoid problems breathing, such as laryngospasm, which may require intubation. Parkinsonism results from DA antagonism and can manifest as resting tremor, cogwheel rigidity, postural instability, and shuffling gait.<xref ref-type="bibr" rid="article-30059.r8">[8]</xref></p>
        <p>Parkinsonism is also treatable with benztropine or diphenhydramine, as well as the&#x000a0;N-methyl-D-aspartate antagonist amantadine. And lastly, typical antipsychotics are associated with an even higher risk of tardive dyskinesia (TD) than atypical antipsychotics. TD is the result of the chronic administration of antipsychotics. The abnormal choreoathetoid movements seen in patients with tardive dyskinesia can&#x000a0;affect&#x000a0;the head, tongue, or face. Tardive dyskinesia is a serious adverse effect as it is not only embarrassing and uncomfortable for the patient, but it is mostly irreversible. If a patient&#x000a0;begins to develop&#x000a0;tardive dyskinesia, the best treatment&#x000a0;is&#x000a0;to stop the antipsychotic medication and&#x000a0;substitute thioridazine for&#x000a0;an atypical antipsychotic with less risk.<xref ref-type="bibr" rid="article-30059.r9">[9]</xref><xref ref-type="bibr" rid="article-30059.r10">[10]</xref></p>
        <p>
<bold>Neuroleptic Malignant Syndrome&#x000a0;</bold>
</p>
        <p>Neuroleptic malignant syndrome (NMS) is another serious side effect of all antipsychotics and occurs more frequently with typical antipsychotics. This adverse effect may occur suddenly. The provider should&#x000a0;monitor&#x000a0;for unstable vital signs, such as tachycardia, fever, muscle rigidity, elevated white blood cell count, and creatinine phosphokinase. If the patient develops NMS, the clinician should immediately&#x000a0;initiate&#x000a0;hydration and supportive therapy. The antipsychotic should be discontinued as well. If necessary,&#x000a0;further management is possible with&#x000a0;dantrolene and bromocriptine.</p>
        <p>
<bold>Electrocardiography Changes</bold>
</p>
        <p>Thioridazine is associated with prolonged QTc intervals, which may have serious or even fatal consequences, such as torsades de pointes. The recommendation is that patients with known prolonged QTc or arrhythmias avoid thioridazine. Before starting this medication, it would be wise to order an electrocardiogram (ECG) and monitor QTc prolongation or other ECG changes during treatment.</p>
        <p>
<bold>Other Side Effects</bold>
</p>
        <p>The development of pigmentary retinopathy is a unique adverse&#x000a0;manifestation associated with thioridazine and not with other antipsychotics.&#x000a0;Patients may have nonspecific symptoms while taking thioridazine, such as dry mouth, dry eyes, sedation, weight gain, dizziness, erectile dysfunction, pruritus, photosensitivity, and constipation. Other rare and more unique side effects of thioridazine include irreversible retinal pigmentation, poikilothermia, and agranulocytosis.</p>
      </sec>
      <sec id="article-30059.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There is a black-box warning for dementia-related psychosis because it may increase the risk of death secondary to cerebrovascular events in the elderly. Thioridazine is associated with a prolonged QT interval. Thus patients with long QT syndrome, QT intervals prolonged to more than 450, or taking&#x000a0;concomitant&#x000a0;medications known to&#x000a0;prolong the QT interval should avoid thioridazine. Also, patients with known heart arrhythmias or hypotensive or hypertensive heart disease should also avoid this medication. Because of drug-drug interactions, the clinician should be aware of the patient's medication profile. Thioridazine is metabolized by the hepatic enzyme cytochrome P450 CYP450 2D6. Medications that inhibit CYP450 2D6 should be used with caution when prescribing thioridazine.&#x000a0;Medications that may affect thioridazine levels include but are not limited to fluoxetine, paroxetine, duloxetine, fluvoxamine, propranolol, citalopram, and pindolol. Another&#x000a0;rare but serious side effect of thioridazine is agranulocytosis. Each patient should be evaluated for abnormal white blood cell counts&#x000a0;pre and post-administration of thioridazine.<xref ref-type="bibr" rid="article-30059.r11">[11]</xref>&#x000a0;Caution is advised in pregnant patients during the third trimester, although teratogenicity is not expected. For breastfeeding, it is recommended to use an alternative agent as there is no data in humans to assess the risk in breast milk.</p>
      </sec>
      <sec id="article-30059.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients require monitoring for medication side effects during treatment, and it is often necessary to screen patients before treatment to obtain baseline results. Since thioridazine can cause significant ECG changes and arrhythmias, it is important to get a baseline ECG and potassium level. Furthermore, an additional ECG is recommended for any change in dose and periodically after that. Another possible side effect of thioridazine is leucopenia, and thus routine complete blood counts are recommended over the course of the initial weeks.<xref ref-type="bibr" rid="article-30059.r12">[12]</xref></p>
        <p>Opthomalogic exams should be implemented as well, as thioridazine can also cause irreversible retinal pigmentation over time. Studies are equivocal regarding the use of thioridazine in pregnancy, so it may be advisable to get a pregnancy test before administering the drug. Thioridazine must be cautioned for use in the third trimester of pregnancy, as it may be associated with a risk of neonatal withdrawal symptoms and extrapyramidal side effects. Furthermore, thioridazine has a narrow therapeutic index, which means it is necessary to carefully monitor each patient for adverse side effects.<xref ref-type="bibr" rid="article-30059.r13">[13]</xref>&#x000a0;In patients with pre-existing or a history of leukopenia or neutropenia, frequent complete blood count with differential is recommended during the initial phase of treatment.<xref ref-type="bibr" rid="article-30059.r14">[14]</xref></p>
      </sec>
      <sec id="article-30059.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Thioridazine is a low-potency typical antipsychotic, like chlorpromazine. Unlike higher-potency antipsychotics, thioridazine has a lower incidence of extrapyramidal side effects. However, lower-potency antipsychotics are more likely to be associated with antimuscarinic, antihistaminic, and antiadrenergic side effects. Thioridazine is metabolized through the liver with a half-life of 24 hours and is excreted in the urine, bile, and feces. The hepatic cytochrome P450 CYP2D6 metabolism of thioridazine is important because it assists in identifying different drug-drug interactions. Thus, it is necessary to evaluate patients and identify medications that may increase or decrease thioridazine levels.<xref ref-type="bibr" rid="article-30059.r15">[15]</xref></p>
      </sec>
      <sec id="article-30059.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The use of thioridazine has declined significantly because of the availability of safer and more effective atypical antipsychotics. When it is used, the entire interprofessional healthcare team needs to be actively involved in therapy. In the current medical environment, its use is almost exclusively limited to refractory schizophrenia which has failed to respond to other therapeutic agents. However,&#x000a0;all clinicians who prescribe thioridazine should first consult with&#x000a0;a psychiatrist for a better option. If the drug&#x000a0;is prescribed, its adverse effects must be closely monitored. This is where nursing staff and pharmacists can be of particular benefit. The pharmacist can also check for drug-drug interactions and report these to the prescriber if present. Nurses can serve as a contact point to the prescriber for other interprofessional healthcare team members and patients, offer patient counseling regarding medication administration and side effects, and document any concerns in the patient's medical record.</p>
        <p>Further, the patient requires education about the side effects and potential drug interactions. Although a rare but serious side effect of thioridazine is agranulocytosis, each patient should be evaluated for abnormal white blood cell counts before use because this medication may exacerbate this problem. If all members of the interprofessional healthcare team collaborate and share information about the patient during thioridazine therapy, the patient is more apt to derive therapeutic benefits leading to improved outcomes with fewer adverse effects.&#x000a0;</p>
      </sec>
      <sec id="article-30059.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30059&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30059">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30059/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30059">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30059.s11">
        <title>References</title>
        <ref id="article-30059.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <chapter-title>Thioridazine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30000170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <chapter-title>Mesoridazine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drobnis</surname>
                <given-names>EZ</given-names>
              </name>
              <name>
                <surname>Nangia</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Psychotropics and Male Reproduction.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2017</year>
            <volume>1034</volume>
            <fpage>63</fpage>
            <page-range>63-101</page-range>
            <pub-id pub-id-type="pmid">29256128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Nasrallah</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Multiple retinal anomalies in schizophrenia.</article-title>
            <source>Schizophr Res</source>
            <year>2018</year>
            <month>May</month>
            <volume>195</volume>
            <fpage>3</fpage>
            <page-range>3-12</page-range>
            <pub-id pub-id-type="pmid">28755877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Purhonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koponen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tiihonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tanskanen</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort.</article-title>
            <source>Pharmacoepidemiol Drug Saf</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1227</fpage>
            <page-range>1227-31</page-range>
            <pub-id pub-id-type="pmid">22941581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amaral</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Viveiros</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>2012</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>376</fpage>
            <page-range>376-80</page-range>
            <pub-id pub-id-type="pmid">22445204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lehmann</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Eggleston</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Validation and Clinical Utility of the hERG IC50:C<sub>max</sub> Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis.</article-title>
            <source>Pharmacotherapy</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-348</page-range>
            <pub-id pub-id-type="pmid">29380488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Euwema</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <chapter-title>Deadly Single Dose Agents</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">28722879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dean</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Thioridazine Therapy and <italic>CYP2D6</italic> Genotypes</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Pratt</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kattman</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Malheiro</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <source>Medical Genetics Summaries [Internet]</source>
            <publisher-name>National Center for Biotechnology Information (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>2</month>
            <day>9</day>
            <pub-id pub-id-type="pmid">28520378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tisdale</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.</article-title>
            <source>Can Pharm J (Ott)</source>
            <year>2016</year>
            <month>May</month>
            <volume>149</volume>
            <issue>3</issue>
            <fpage>139</fpage>
            <page-range>139-52</page-range>
            <pub-id pub-id-type="pmid">27212965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <article-title>Thioridazine and severe cardiac arrhythmia.</article-title>
            <source>Prescrire Int</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>56</issue>
            <fpage>183</fpage>
            <page-range>183-4</page-range>
            <pub-id pub-id-type="pmid">11824444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristiansen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dastidar</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Palchoudhuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Phenothiazines as a solution for multidrug resistant tuberculosis: From the origin to present.</article-title>
            <source>Int Microbiol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">26415662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiang</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Ungvari</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Si</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Kua</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Udomratn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chee</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Sartorius</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Shinfuku</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009.</article-title>
            <source>Hum Psychopharmacol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-9</page-range>
            <pub-id pub-id-type="pmid">25611192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Wager</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Haematological safety of antipsychotic drugs.</article-title>
            <source>J Psychopharmacol</source>
            <year>1998</year>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>283</fpage>
            <page-range>283-8</page-range>
            <pub-id pub-id-type="pmid">10958256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30059.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thanacoody</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Thioridazine: the good and the bad.</article-title>
            <source>Recent Pat Antiinfect Drug Discov</source>
            <year>2011</year>
            <month>May</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-8</page-range>
            <pub-id pub-id-type="pmid">21548877</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
